About: Radiopharm Theranostics Limited a clinical-stage radiotherapeutics company, engages in the development of radiopharmaceutical products for diagnostic and therapeutic uses in areas with high unmet medical needs in the United States. The company develops RAD101, a pivalate brain metastasis diagnostic; RAD102, a pivalate therapeutic; RAD201a, a Nano-mAb HER-2 breast diagnostic; RAD202, a Nano-mAb HER-2 breast therapeutic; RAD203, a Nano-mAb PDL1 non-small cell lung diagnostic; and RAD204, a Nano-mAb PDL1 non-small cell lung therapeutic. It is also developing RAD301 and RAD302, which are Avß6-Integrin pancreatic diagnostic and therapeutic products; RAD401, a PSA-mAb prostate cancer diagnostic; and RAD402, a PSA-mAb prostate cancer therapeutic. The company was incorporated in 2021 and is based in Carlton, Australia.
Sector: Healthcare
Industry: Biotechnology
Latest price: $0.77 (+1.00%)
RADX NASDAQ Radiopharm Theranostics Limited American Depositary Shares
Radiopharm Theranostics Limited American Depositary Shares share price
Atividade de preço de RADX
Último preço
$ 0,770
Variação (24h)
0,01 USD (1,00%)
Volume
54.41K
Volume (média 4 sem.)
-
Abertura
$ 0,74
Variação do dia
$ 0,73 - $ 0,81
Fechamento anterior
$ 0,76
Último negócio
16 Nov, 9:13 pm GMT+0
Atrasado
16 Nov, 9:13 pm GMT+0
RADX price performance
Atrasado
16 Nov, 9:13 pm GMT+0
RADX details
quote.marketSignals